Argent BioPharma Ltd on Tuesday celebrated the approval of its shares to trading in the US, and also announced the appointment of its new chief financial officer.

Argent is a drug discovery company within the biopharmaceutical sector.

Its shares have been approved to trade on the OTCQB Venture Market, and began doing so last Thursday under the ticker ’MGCLF’.

According to Chief Executive Officer Roby Zomer, cross-trading on the OTCQB ‘will increase liquidity and significantly enhance the ability of US based investors to access and trade Argent BioPharma’s shares during a period in which we are actively progressing our key drug development.’

‘Trading on OTCQB will also, we believe, serve to diversify the share register and increase exposure to a broader range of investors,’ Zomer added.

Also on Tuesday, Argent announced that it has appointed Igor Bluvstein as chief financial officer. Bluvstein previously served as the CFO at MDD Group.

Shares in Argent BioPharma were down 7.0% at 20.00 pence each in London on Tuesday afternoon.

Copyright 2024 Alliance News Ltd. All Rights Reserved.